Will Carroll, Pharm.D., of Sutter Health says future pharmacy leaders need business, finance and AI skills, and health systems need real sponsorship.
News|Articles|November 12, 2010
Guidance emerges on specific types of combo therapy for hypertension
With single-pill, fixed-dose combinations of antihypertensive agents, as well as triple-therapy, single-pill agents emerging, updated guidance on specific types of combination therapy for hypertension has emerged.
Advertisement
Advertisement
Related to this article
Will Carroll, Pharm.D., of Sutter Health says pharmacy is often handed strategy to execute instead of shaping it, and must show value in C-suite terms.
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in cardiovascular prevention.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, is now the biggest barrier.
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Robotic lobectomies grew from 49% to 70% of cases from 2020 to 2024 as access and training expanded, says Staci Beamer, M.D., of HonorHealth.
AI analyzes single-lead ECGs from sleep studies to predict atrial fibrillation, heart failure, and mortality risk, enabling scalable cardiovascular disease screening.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
Will Carroll, Pharm.D., on developing future pharmacy executives | HSES 2026
3
Will Carroll, Pharm.D., on moving pharmacy upstream in strategy | HSES 2026
4
Ty Gluckman, M.D., on what the new lipid guidelines mean for payers | HSES 2026
5